Cytosorbents Corporation (CTSO) Financial Ratios
20 years of historical data (2005–2024) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.99
-2% vs avg
5yr avg: 3.06
30Y Low0.9·High80.5
ROE
↓
-120.5%
↑-77% vs avg
5yr avg: -68.2%
30Y Low-309%·High-19%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CTSO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cytosorbents Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $38M | $50M | $50M | $68M | $182M | $309M | $124M | $248M | $179M | $139M | $139M |
| Enterprise Value | $62M | $73M | $54M | $64M | $143M | $239M | $129M | $236M | $172M | $138M | $133M |
| P/E Ratio → | -1.60 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.07 | 1.39 | 1.59 | 1.95 | 4.53 | 7.84 | 5.45 | 12.26 | 13.41 | 16.89 | 34.18 |
| P/B Ratio | 2.99 | 4.46 | 2.13 | 1.91 | 2.90 | 3.91 | 36.33 | 14.66 | 17.49 | — | 16.88 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CTSO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.06 | 1.73 | 1.83 | 3.57 | 6.06 | 5.64 | 11.64 | 12.87 | 16.85 | 32.87 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CTSO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cytosorbents Corporation earns an operating margin of -47.2%. Operating margins have expanded from -90.9% to -47.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -120.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.6% | 70.6% | 70.6% | 59.8% | 72.5% | 72.0% | 67.7% | 63.0% | 58.8% | 51.8% | 45.4% |
| Operating Margin | -47.2% | -47.2% | -102.8% | -90.9% | -56.7% | -26.3% | -83.3% | -77.0% | -73.6% | -140.0% | -229.4% |
| Net Profit Margin | -58.2% | -58.2% | -94.1% | -94.6% | -61.2% | -19.9% | -84.6% | -85.0% | -63.2% | -145.5% | -200.5% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -120.5% | -120.5% | -99.7% | -67.0% | -34.6% | -19.0% | -189.3% | -126.6% | -172.9% | -308.6% | -133.6% |
| ROA | -41.2% | -41.2% | -50.2% | -43.0% | -27.4% | -13.4% | -64.1% | -60.5% | -50.1% | -114.0% | -82.5% |
| ROIC | -40.5% | -40.5% | -81.3% | -84.8% | -103.1% | -93.9% | -232.5% | -314.2% | -694.6% | -826.3% | -429.2% |
| ROCE | -44.0% | -44.0% | -69.3% | -48.7% | -29.2% | -21.3% | -86.9% | -73.4% | -99.1% | -194.5% | -152.8% |
CTSO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $24M ($27M total debt minus $3M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.42 | 2.42 | 0.79 | 0.52 | 0.22 | 0.01 | 4.84 | 0.59 | 0.97 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.13 | 0.18 | -0.11 | -0.61 | -0.89 | 1.26 | -0.73 | -0.71 | — | -0.65 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -12.00 | -12.00 | -202.35 | — | — | -8.63 | -18.36 | -10.67 | -13.14 | -49.58 | -1000.29 |
CTSO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cytosorbents Corporation's current ratio of 2.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.48x to 2.20x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.20 | 2.20 | 1.77 | 3.48 | 4.70 | 8.12 | 2.10 | 4.32 | 2.64 | 1.29 | 3.24 |
| Quick Ratio | 1.92 | 1.92 | 1.51 | 3.12 | 4.35 | 7.86 | 1.89 | 4.20 | 2.54 | 1.15 | 2.85 |
| Cash Ratio | 0.33 | 0.33 | 0.97 | 2.28 | 3.81 | 7.03 | 1.23 | 3.42 | 2.21 | 0.86 | 2.47 |
| Asset Turnover | — | 0.75 | 0.58 | 0.55 | 0.45 | 0.44 | 0.83 | 0.62 | 0.56 | 0.85 | 0.36 |
| Inventory Turnover | 3.83 | 3.83 | 2.48 | 4.03 | 2.32 | 4.13 | 3.48 | 8.99 | 6.94 | 4.74 | 1.86 |
| Days Sales Outstanding | — | 75.06 | 71.12 | 59.61 | 41.16 | 47.73 | 71.62 | 71.07 | 60.17 | 63.76 | 58.40 |
CTSO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cytosorbents Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 0.2% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $54M | $45M | $44M | $43M | $39M | $32M | $31M | $28M | $25M | $25M |
Peer Comparison
Compare CTSO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CTSOYou | $38M | -1.6 | — | — | 70.6% | -47.2% | -120.5% | -40.5% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 MASI | $9B | -63.8 | 27.7 | 47.3 | 61.9% | 20.5% | -17.1% | 16.5% | 1.6 |
 ICUI | $3B | 4186.1 | 12.8 | 33.5 | 36.8% | 4.8% | 0.0% | 2.5% | 4.3 |
 LMAT | $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 BAX | $9B | -10.0 | 25.4 | 28.0 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 KRMD | $207M | -77.8 | — | — | 60.3% | -7.2% | -15.6% | -19.5% | — |
 BDX | $56B | 26.3 | 14.7 | 20.8 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
See CTSO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTSO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTSO vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonCTSO — Frequently Asked Questions
Quick answers to the most common questions about buying CTSO stock.
What is Cytosorbents Corporation's P/E ratio?
Cytosorbents Corporation's current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
What is Cytosorbents Corporation's ROE?
Cytosorbents Corporation's return on equity (ROE) is -120.5%. The historical average is -158.7%.
Is CTSO stock overvalued?
Based on historical data, Cytosorbents Corporation is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Cytosorbents Corporation's profit margins?
Cytosorbents Corporation has 70.6% gross margin and -47.2% operating margin.